Levy Y, Uziel Y, Zandman G G, Amital H, Sherer Y, Langevitz P, Goldman B, Shoenfeld Y
Department of Medicine B and the Centre for Autoimmune Diseases, Sheba Medical Centre Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Ann Rheum Dis. 2003 Dec;62(12):1221-3. doi: 10.1136/ard.2002.003996.
Peripheral neuropathy is a prominent feature of the systemic and secondary vasculitides. Usually, it is responsive to corticosteroids, but in certain cases it may be resistant to corticosteroid or immunosuppressive treatment, or both.
To present patients who exhibited various inflammatory diseases accompanied with vasculitic peripheral neuropathies for which intravenous immunoglobulin (IVIg) was used for treatment.
Six patients with Sjögren's syndrome, systemic lupus erythematosus (SLE), vaccination induced vasculitis, Churg-Strauss vasculitis, mixed cryoglobulinaemia associated with hepatitis C infection, or sarcoidosis were included. All developed vasculitic peripheral neuropathy, and were treated with high dose IVIg (2 g/kg body weight). The patients were followed up for 1-5 years after this treatment.
In four patients (Sjögren's syndrome, Churg-Strauss vasculitis, SLE, and vaccination induced vasculitis) the neuropathy resolved after IVIg treatment.
IVIg may be beneficial in cases of resistant vasculitic peripheral neuropathy. IVIg should probably be considered as a sole or adjuvant treatment for patients with contraindications to conventional treatment, or alternatively, for patients in whom conventional treatment has failed.
周围神经病变是系统性和继发性血管炎的一个突出特征。通常,它对皮质类固醇有反应,但在某些情况下,它可能对皮质类固醇或免疫抑制治疗,或两者均有抵抗性。
介绍表现为各种炎症性疾病伴血管炎性周围神经病变且使用静脉注射免疫球蛋白(IVIg)进行治疗的患者。
纳入6例患有干燥综合征、系统性红斑狼疮(SLE)、疫苗诱导性血管炎、变应性肉芽肿性血管炎、丙型肝炎感染相关的混合性冷球蛋白血症或结节病的患者。所有患者均发生血管炎性周围神经病变,并接受高剂量IVIg(2 g/kg体重)治疗。治疗后对患者进行了1至5年的随访。
4例患者(干燥综合征、变应性肉芽肿性血管炎、SLE和疫苗诱导性血管炎)在IVIg治疗后神经病变得到缓解。
IVIg可能对抵抗性血管炎性周围神经病变有效。对于有传统治疗禁忌证的患者,或者传统治疗失败的患者,IVIg可能应被视为单一治疗或辅助治疗。